May 4th, 2022 (Earnings Report)Dear Reader,HealthTechMovers.com just identified several healthtech stocks that are expected to release earnings this week.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
1Life Healthcare
Symbol: ONEM
Recent Price: $$7.42
Average Analyst Price Target: $15.58 (109.97%)
Market Cap: $$1.44B
Last Year's EPS: -$0.29
Consensus EPS Forecast: -$0.46
Expected Earnings Date: May 03 2022
Recent Analyst Action: David S, analyst at Truist Financial, reiterates coverage on 1Life Healthcare (ONEM) in the Healthcare sector with a Buy rating and a price target of n/a (3 weeks ago).
TipRanks.com also reports that 1Life Healthcare currently has 15 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $15.58 . The target pricing ranges from a high forecast of $25.00 down to a low forecast of $10.00. 1Life Healthcare (ONEM)’s last closing price was $$7.42 which would put the average price target at 109.97% upside.Here are 3rd party ratings for ONEM:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Top 36% (90 out of 253)
--------------------------------------------------------------------------
Amryt Pharma
Symbol: AMYT
Recent Price: $$8.41
Average Analyst Price Target: $18.33 (117.95%)
Market Cap: $$539.42M
Last Year's EPS: -$0.45
Consensus EPS Forecast: -$0.02
Expected Earnings Date: May 03 2022
Recent Analyst Action: Douglas Tsao, analyst at H.C. Wainwright, reiterates coverage on Amryt Pharma (AMYT) in the Healthcare sector with a Buy rating and a price target of $ 18 (1 week ago).
TipRanks.com also reports that Amryt Pharma currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $18.33 . The target pricing ranges from a high forecast of $19.00 down to a low forecast of $18.00. Amryt Pharma (AMYT)’s last closing price was $$8.41 which would put the average price target at 117.95% upside.Here are 3rd party ratings for AMYT:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 40% (152 out of 253)
--------------------------------------------------------------------------
Apellis Pharmaceuticals
Symbol: APLS
Recent Price: $$44.61
Average Analyst Price Target: $75.89 (70.12%)
Market Cap: $$4.75B
Last Year's EPS: -$2.32
Consensus EPS Forecast: -$1.33
Expected Earnings Date: May 03 2022
Recent Analyst Action: Tazeen Ahmad, analyst at Bank of America Securities, reiterates coverage on Apellis Pharmaceuticals (APLS) in the Healthcare sector with a Buy rating and a price target of $ 68 (2 weeks ago).
TipRanks.com also reports that Apellis Pharmaceuticals currently has 10 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $75.89 . The target pricing ranges from a high forecast of $114.00 down to a low forecast of $40.00. Apellis Pharmaceuticals (APLS)’s last closing price was $$44.61 which would put the average price target at 70.12% upside.Here are 3rd party ratings for APLS:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Bottom 40% (152 out of 253)
--------------------------------------------------------------------------
BioAtla
Symbol: BCAB
Recent Price: $$3.83
Average Analyst Price Target: $41.33 (979.11%)
Market Cap: $$143.18M
Last Year's EPS: -$0.56
Consensus EPS Forecast: -$0.67
Expected Earnings Date: May 03 2022
Recent Analyst Action: Arthur He, analyst at H.C. Wainwright, reiterates coverage on BioAtla (BCAB) in the Healthcare sector with a Buy rating and a price target of $ 25 (1 month ago).
TipRanks.com also reports that BioAtla currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $41.33 . The target pricing ranges from a high forecast of $68.00 down to a low forecast of $25.00. BioAtla (BCAB)’s last closing price was $$3.83 which would put the average price target at 979.11% upside.Here are 3rd party ratings for BCAB:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Bottom 40% (152 out of 253)
--------------------------------------------------------------------------
Cytokinetics
Symbol: CYTK
Recent Price: $$40
Average Analyst Price Target: $57.67 (44.18%)
Market Cap: $$3.42B
Last Year's EPS: -$0.66
Consensus EPS Forecast: -$0.94
Expected Earnings Date: May 03 2022
Recent Analyst Action: Justin Kim, analyst at Oppenheimer, reiterates coverage on Cytokinetics (CYTK) in the Healthcare sector with a Buy rating and a price target of $ 57 (5 days ago).
TipRanks.com also reports that Cytokinetics currently has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $57.67 . The target pricing ranges from a high forecast of $75.00 down to a low forecast of $48.00. Cytokinetics (CYTK)’s last closing price was $$40 which would put the average price target at 44.18% upside.Here are 3rd party ratings for CYTK:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 40% (152 out of 253)
--------------------------------------------------------------------------
Envista Holdings
Symbol: NVST
Recent Price: $$40.67
Average Analyst Price Target: $55.50 (36.46%)
Market Cap: $$6.61B
Last Year's EPS: $0.54
Consensus EPS Forecast: $0.44
Expected Earnings Date: May 03 2022
Recent Analyst Action: Jeff Johnson, analyst at Robert W. Baird, reiterates coverage on Envista Holdings (NVST) in the Healthcare sector with a Buy rating and a price target of $ 54 (2 weeks ago).
TipRanks.com also reports that Envista Holdings currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $55.50 . The target pricing ranges from a high forecast of $60.00 down to a low forecast of $50.00. Envista Holdings (NVST)’s last closing price was $$40.67 which would put the average price target at 36.46% upside.Here are 3rd party ratings for NVST:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Bottom 32% (171 out of 253)
--------------------------------------------------------------------------
Fate Therapeutics
Symbol: FATE
Recent Price: $$28.78
Average Analyst Price Target: $81.67 (183.77%)
Market Cap: $$2.78B
Last Year's EPS: -$0.48
Consensus EPS Forecast: -$0.77
Expected Earnings Date: May 03 2022
Recent Analyst Action: Daina Graybosch, analyst at Leerink Partners, reiterates coverage on Fate Therapeutics (FATE) in the Healthcare sector with a Buy rating and a price target of $ 79 (1 week ago).
TipRanks.com also reports that Fate Therapeutics currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $81.67 . The target pricing ranges from a high forecast of $115.00 down to a low forecast of $50.00. Fate Therapeutics (FATE)’s last closing price was $$28.78 which would put the average price target at 183.77% upside.Here are 3rd party ratings for FATE:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 40% (152 out of 253)
--------------------------------------------------------------------------
Global Blood Therapeutics
Symbol: GBT
Recent Price: $$32.04
Average Analyst Price Target: $64.17 (100.28%)
Market Cap: $$2.09B
Last Year's EPS: -$1.21
Consensus EPS Forecast: -$1.31
Expected Earnings Date: May 03 2022
Recent Analyst Action: Li Watsek, analyst at Cantor Fitzgerald, reiterates coverage on Global Blood Therapeutics (GBT) in the Healthcare sector with a Buy rating and a price target of $ 75 (6 days ago).
TipRanks.com also reports that Global Blood Therapeutics currently has 13 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $64.17 . The target pricing ranges from a high forecast of $86.00 down to a low forecast of $31.00. Global Blood Therapeutics (GBT)’s last closing price was $$32.04 which would put the average price target at 100.28% upside.Here are 3rd party ratings for GBT:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Sell, Bottom 40% (152 out of 253)
--------------------------------------------------------------------------
Horizon Therapeutics
Symbol: HZNP
Recent Price: $$94.72
Average Analyst Price Target: $145.57 (53.68%)
Market Cap: $$21.71B
Last Year's EPS: $0.03
Consensus EPS Forecast: $1.14
Expected Earnings Date: May 03 2022
Recent Analyst Action: Derek Archila, analyst at Wells Fargo, reiterates coverage on Horizon Therapeutics (HZNP) in the Healthcare sector with a Buy rating and a price target of $ 133 (3 weeks ago).
TipRanks.com also reports that Horizon Therapeutics currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $145.57 . The target pricing ranges from a high forecast of $169.00 down to a low forecast of $133.00. Horizon Therapeutics (HZNP)’s last closing price was $$94.72 which would put the average price target at 53.68% upside.Here are 3rd party ratings for HZNP:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Buy, Bottom 40% (152 out of 253)
--------------------------------------------------------------------------
Inari Medical
Symbol: NARI
Recent Price: $$79.76
Average Analyst Price Target: $109.80 (37.66%)
Market Cap: $$4.23B
Last Year's EPS: $0.13
Consensus EPS Forecast: -$0.08
Expected Earnings Date: May 03 2022
Recent Analyst Action: Danielle Antalffy, analyst at Leerink Partners, reiterates coverage on Inari Medical (NARI) in the Healthcare sector with a Buy rating and a price target of $ 110 (2 weeks ago).
TipRanks.com also reports that Inari Medical currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $109.80 . The target pricing ranges from a high forecast of $130.00 down to a low forecast of $96.00. Inari Medical (NARI)’s last closing price was $$79.76 which would put the average price target at 37.66% upside.Here are 3rd party ratings for NARI:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Buy, Bottom 36% (162 out of 253)
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com
